<?xml version='1.0' encoding='utf-8'?>
<document id="10445377"><sentence text="In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine."><entity charOffset="69-80" id="DDI-PubMed.10445377.s1.e0" text="fluvoxamine" /><entity charOffset="85-94" id="DDI-PubMed.10445377.s1.e1" text="clozapine" /><pair ddi="false" e1="DDI-PubMed.10445377.s1.e0" e2="DDI-PubMed.10445377.s1.e0" /><pair ddi="false" e1="DDI-PubMed.10445377.s1.e0" e2="DDI-PubMed.10445377.s1.e1" /></sentence><sentence text="The drug-drug interaction between fluvoxamine (FLV) and clozapine (CLZ) was evaluated by in-vitro and in-vivo methods"><entity charOffset="34-45" id="DDI-PubMed.10445377.s2.e0" text="fluvoxamine" /><entity charOffset="47-50" id="DDI-PubMed.10445377.s2.e1" text="FLV" /><entity charOffset="56-65" id="DDI-PubMed.10445377.s2.e2" text="clozapine" /><entity charOffset="67-70" id="DDI-PubMed.10445377.s2.e3" text="CLZ" /><pair ddi="false" e1="DDI-PubMed.10445377.s2.e0" e2="DDI-PubMed.10445377.s2.e0" /><pair ddi="false" e1="DDI-PubMed.10445377.s2.e0" e2="DDI-PubMed.10445377.s2.e1" /><pair ddi="false" e1="DDI-PubMed.10445377.s2.e0" e2="DDI-PubMed.10445377.s2.e2" /><pair ddi="false" e1="DDI-PubMed.10445377.s2.e0" e2="DDI-PubMed.10445377.s2.e3" /><pair ddi="false" e1="DDI-PubMed.10445377.s2.e1" e2="DDI-PubMed.10445377.s2.e1" /><pair ddi="false" e1="DDI-PubMed.10445377.s2.e1" e2="DDI-PubMed.10445377.s2.e2" /><pair ddi="false" e1="DDI-PubMed.10445377.s2.e1" e2="DDI-PubMed.10445377.s2.e3" /><pair ddi="false" e1="DDI-PubMed.10445377.s2.e2" e2="DDI-PubMed.10445377.s2.e2" /><pair ddi="false" e1="DDI-PubMed.10445377.s2.e2" e2="DDI-PubMed.10445377.s2.e3" /></sentence><sentence text=" In-vitro studies were conducted using human hepatic microsomal preparations with standard chemical inhibitors of the cytochrome P450 (CYP 450) isozyme system" /><sentence text=" Furafyline, FLV, troleandomycin (TAO) and erythromycin were used as the chemical inhibitors"><entity charOffset="1-11" id="DDI-PubMed.10445377.s4.e0" text="Furafyline" /><entity charOffset="13-16" id="DDI-PubMed.10445377.s4.e1" text="FLV" /><entity charOffset="18-32" id="DDI-PubMed.10445377.s4.e2" text="troleandomycin" /><entity charOffset="34-37" id="DDI-PubMed.10445377.s4.e3" text="TAO" /><entity charOffset="43-55" id="DDI-PubMed.10445377.s4.e4" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.10445377.s4.e0" e2="DDI-PubMed.10445377.s4.e0" /><pair ddi="false" e1="DDI-PubMed.10445377.s4.e0" e2="DDI-PubMed.10445377.s4.e1" /><pair ddi="false" e1="DDI-PubMed.10445377.s4.e0" e2="DDI-PubMed.10445377.s4.e2" /><pair ddi="false" e1="DDI-PubMed.10445377.s4.e0" e2="DDI-PubMed.10445377.s4.e3" /><pair ddi="false" e1="DDI-PubMed.10445377.s4.e0" e2="DDI-PubMed.10445377.s4.e4" /><pair ddi="false" e1="DDI-PubMed.10445377.s4.e1" e2="DDI-PubMed.10445377.s4.e1" /><pair ddi="false" e1="DDI-PubMed.10445377.s4.e1" e2="DDI-PubMed.10445377.s4.e2" /><pair ddi="false" e1="DDI-PubMed.10445377.s4.e1" e2="DDI-PubMed.10445377.s4.e3" /><pair ddi="false" e1="DDI-PubMed.10445377.s4.e1" e2="DDI-PubMed.10445377.s4.e4" /><pair ddi="false" e1="DDI-PubMed.10445377.s4.e2" e2="DDI-PubMed.10445377.s4.e2" /><pair ddi="false" e1="DDI-PubMed.10445377.s4.e2" e2="DDI-PubMed.10445377.s4.e3" /><pair ddi="false" e1="DDI-PubMed.10445377.s4.e2" e2="DDI-PubMed.10445377.s4.e4" /><pair ddi="false" e1="DDI-PubMed.10445377.s4.e3" e2="DDI-PubMed.10445377.s4.e3" /><pair ddi="false" e1="DDI-PubMed.10445377.s4.e3" e2="DDI-PubMed.10445377.s4.e4" /></sentence><sentence text=" For the in-vivo study, nine male schizophrenic patients were administered a single dose of CLZ 50 mg on two separate occasions with a 2-week FLV treatment of 50 mg twice a day in between each CLZ dose"><entity charOffset="142-153" id="DDI-PubMed.10445377.s5.e0" text="FLV" /><entity charOffset="92-103" id="DDI-PubMed.10445377.s5.e1" text="CLZ" /><entity charOffset="193-204" id="DDI-PubMed.10445377.s5.e2" text="CLZ" /><pair ddi="false" e1="DDI-PubMed.10445377.s5.e1" e2="DDI-PubMed.10445377.s5.e1" /><pair ddi="false" e1="DDI-PubMed.10445377.s5.e1" e2="DDI-PubMed.10445377.s5.e0" /><pair ddi="false" e1="DDI-PubMed.10445377.s5.e1" e2="DDI-PubMed.10445377.s5.e2" /><pair ddi="false" e1="DDI-PubMed.10445377.s5.e0" e2="DDI-PubMed.10445377.s5.e0" /><pair ddi="false" e1="DDI-PubMed.10445377.s5.e0" e2="DDI-PubMed.10445377.s5.e2" /></sentence><sentence text=" Blood samples were obtained over 48 h following CLZ administration"><entity charOffset="49-51" id="DDI-PubMed.10445377.s6.e0" text="CLZ" /></sentence><sentence text=" CLZ and its two principle metabolites, clozapine N-oxide (CNO) and desmethylclozapine (DCLZ), were measured by high performance liquid chromatography with ultraviolet detection for both in-vitro and in-vivo studies"><entity charOffset="40-57" id="DDI-PubMed.10445377.s7.e0" text="clozapine N-oxide" /><entity charOffset="59-62" id="DDI-PubMed.10445377.s7.e1" text="CNO" /><entity charOffset="68-86" id="DDI-PubMed.10445377.s7.e2" text="desmethylclozapine" /><entity charOffset="88-92" id="DDI-PubMed.10445377.s7.e3" text="DCLZ" /><entity charOffset="1-4" id="DDI-PubMed.10445377.s7.e4" text="CLZ" /><entity charOffset="89-92" id="DDI-PubMed.10445377.s7.e5" text="CLZ" /><pair ddi="false" e1="DDI-PubMed.10445377.s7.e4" e2="DDI-PubMed.10445377.s7.e4" /><pair ddi="false" e1="DDI-PubMed.10445377.s7.e4" e2="DDI-PubMed.10445377.s7.e0" /><pair ddi="false" e1="DDI-PubMed.10445377.s7.e4" e2="DDI-PubMed.10445377.s7.e1" /><pair ddi="false" e1="DDI-PubMed.10445377.s7.e4" e2="DDI-PubMed.10445377.s7.e2" /><pair ddi="false" e1="DDI-PubMed.10445377.s7.e4" e2="DDI-PubMed.10445377.s7.e3" /><pair ddi="false" e1="DDI-PubMed.10445377.s7.e4" e2="DDI-PubMed.10445377.s7.e5" /><pair ddi="false" e1="DDI-PubMed.10445377.s7.e0" e2="DDI-PubMed.10445377.s7.e0" /><pair ddi="false" e1="DDI-PubMed.10445377.s7.e0" e2="DDI-PubMed.10445377.s7.e1" /><pair ddi="false" e1="DDI-PubMed.10445377.s7.e0" e2="DDI-PubMed.10445377.s7.e2" /><pair ddi="false" e1="DDI-PubMed.10445377.s7.e0" e2="DDI-PubMed.10445377.s7.e3" /><pair ddi="false" e1="DDI-PubMed.10445377.s7.e0" e2="DDI-PubMed.10445377.s7.e5" /><pair ddi="false" e1="DDI-PubMed.10445377.s7.e1" e2="DDI-PubMed.10445377.s7.e1" /><pair ddi="false" e1="DDI-PubMed.10445377.s7.e1" e2="DDI-PubMed.10445377.s7.e2" /><pair ddi="false" e1="DDI-PubMed.10445377.s7.e1" e2="DDI-PubMed.10445377.s7.e3" /><pair ddi="false" e1="DDI-PubMed.10445377.s7.e1" e2="DDI-PubMed.10445377.s7.e5" /><pair ddi="false" e1="DDI-PubMed.10445377.s7.e2" e2="DDI-PubMed.10445377.s7.e2" /><pair ddi="false" e1="DDI-PubMed.10445377.s7.e2" e2="DDI-PubMed.10445377.s7.e3" /><pair ddi="false" e1="DDI-PubMed.10445377.s7.e2" e2="DDI-PubMed.10445377.s7.e5" /><pair ddi="false" e1="DDI-PubMed.10445377.s7.e3" e2="DDI-PubMed.10445377.s7.e3" /><pair ddi="false" e1="DDI-PubMed.10445377.s7.e3" e2="DDI-PubMed.10445377.s7.e5" /></sentence><sentence text=" The in-vitro formation of DCLZ was inhibited by furafyline and FLV by 42"><entity charOffset="49-59" id="DDI-PubMed.10445377.s8.e0" text="furafyline" /><entity charOffset="64-73" id="DDI-PubMed.10445377.s8.e1" text="FLV" /><entity charOffset="28-37" id="DDI-PubMed.10445377.s8.e2" text="CLZ" /><entity charOffset="27-36" id="DDI-PubMed.10445377.s8.e3" text="DCLZ" /><pair ddi="false" e1="DDI-PubMed.10445377.s8.e3" e2="DDI-PubMed.10445377.s8.e3" /><pair ddi="false" e1="DDI-PubMed.10445377.s8.e3" e2="DDI-PubMed.10445377.s8.e2" /><pair ddi="false" e1="DDI-PubMed.10445377.s8.e3" e2="DDI-PubMed.10445377.s8.e0" /><pair ddi="false" e1="DDI-PubMed.10445377.s8.e3" e2="DDI-PubMed.10445377.s8.e1" /><pair ddi="false" e1="DDI-PubMed.10445377.s8.e2" e2="DDI-PubMed.10445377.s8.e2" /><pair ddi="false" e1="DDI-PubMed.10445377.s8.e2" e2="DDI-PubMed.10445377.s8.e0" /><pair ddi="false" e1="DDI-PubMed.10445377.s8.e2" e2="DDI-PubMed.10445377.s8.e1" /><pair ddi="false" e1="DDI-PubMed.10445377.s8.e0" e2="DDI-PubMed.10445377.s8.e0" /><pair ddi="false" e1="DDI-PubMed.10445377.s8.e0" e2="DDI-PubMed.10445377.s8.e1" /></sentence><sentence text="0% and 48" /><sentence text="5% (P&lt;0" /><sentence text="01), respectively" /><sentence text=" TAO and erythromycin had only modest inhibition effects on DCLZ formation of 18"><entity charOffset="9-21" id="DDI-PubMed.10445377.s12.e0" text="erythromycin" /><entity charOffset="61-72" id="DDI-PubMed.10445377.s12.e1" text="CLZ" /><entity charOffset="1-12" id="DDI-PubMed.10445377.s12.e2" text="TAO" /><entity charOffset="60-71" id="DDI-PubMed.10445377.s12.e3" text="DCLZ" /><pair ddi="false" e1="DDI-PubMed.10445377.s12.e2" e2="DDI-PubMed.10445377.s12.e2" /><pair ddi="false" e1="DDI-PubMed.10445377.s12.e2" e2="DDI-PubMed.10445377.s12.e0" /><pair ddi="false" e1="DDI-PubMed.10445377.s12.e2" e2="DDI-PubMed.10445377.s12.e3" /><pair ddi="false" e1="DDI-PubMed.10445377.s12.e2" e2="DDI-PubMed.10445377.s12.e1" /><pair ddi="false" e1="DDI-PubMed.10445377.s12.e0" e2="DDI-PubMed.10445377.s12.e0" /><pair ddi="false" e1="DDI-PubMed.10445377.s12.e0" e2="DDI-PubMed.10445377.s12.e3" /><pair ddi="false" e1="DDI-PubMed.10445377.s12.e0" e2="DDI-PubMed.10445377.s12.e1" /><pair ddi="false" e1="DDI-PubMed.10445377.s12.e3" e2="DDI-PubMed.10445377.s12.e3" /><pair ddi="false" e1="DDI-PubMed.10445377.s12.e3" e2="DDI-PubMed.10445377.s12.e1" /></sentence><sentence text="3% and 21" /><sentence text="0% (P = NS), respectively" /><sentence text=" CNO in-vitro formation was significantly reduced by TAO and erythromycin by 44"><entity charOffset="53-56" id="DDI-PubMed.10445377.s15.e0" text="TAO" /><entity charOffset="61-73" id="DDI-PubMed.10445377.s15.e1" text="erythromycin" /><entity charOffset="1-12" id="DDI-PubMed.10445377.s15.e2" text="CNO" /><pair ddi="false" e1="DDI-PubMed.10445377.s15.e2" e2="DDI-PubMed.10445377.s15.e2" /><pair ddi="false" e1="DDI-PubMed.10445377.s15.e2" e2="DDI-PubMed.10445377.s15.e0" /><pair ddi="false" e1="DDI-PubMed.10445377.s15.e2" e2="DDI-PubMed.10445377.s15.e1" /><pair ddi="false" e1="DDI-PubMed.10445377.s15.e0" e2="DDI-PubMed.10445377.s15.e0" /><pair ddi="false" e1="DDI-PubMed.10445377.s15.e0" e2="DDI-PubMed.10445377.s15.e1" /></sentence><sentence text="5% and 45" /><sentence text="0% (P&lt;0" /><sentence text="01), respectively" /><sentence text=" Furafyline and FLV had only modest effects of 19"><entity charOffset="1-11" id="DDI-PubMed.10445377.s19.e0" text="Furafyline" /><entity charOffset="16-25" id="DDI-PubMed.10445377.s19.e1" text="FLV" /><pair ddi="false" e1="DDI-PubMed.10445377.s19.e0" e2="DDI-PubMed.10445377.s19.e0" /><pair ddi="false" e1="DDI-PubMed.10445377.s19.e0" e2="DDI-PubMed.10445377.s19.e1" /></sentence><sentence text="2% and 8" /><sentence text="5% (P = NS), respectively" /><sentence text=" In schizophrenic patients, FLV resulted in a pronounced increased in CLZ plasma concentrations with the total mean CLZ AUC increased by a factor of 2"><entity charOffset="28-30" id="DDI-PubMed.10445377.s22.e0" text="FLV" /><entity charOffset="70-72" id="DDI-PubMed.10445377.s22.e1" text="CLZ" /><entity charOffset="116-118" id="DDI-PubMed.10445377.s22.e2" text="CLZ" /><pair ddi="false" e1="DDI-PubMed.10445377.s22.e0" e2="DDI-PubMed.10445377.s22.e0" /><pair ddi="false" e1="DDI-PubMed.10445377.s22.e0" e2="DDI-PubMed.10445377.s22.e1" /><pair ddi="false" e1="DDI-PubMed.10445377.s22.e0" e2="DDI-PubMed.10445377.s22.e2" /><pair ddi="false" e1="DDI-PubMed.10445377.s22.e1" e2="DDI-PubMed.10445377.s22.e1" /><pair ddi="false" e1="DDI-PubMed.10445377.s22.e1" e2="DDI-PubMed.10445377.s22.e2" /></sentence><sentence text="58 from 780" /><sentence text="8 ng/ml per hour to 2218" /><sentence text="0 ng/ml per hour (P&lt;0" /><sentence text="001)" /><sentence text=" All patients were sedated during combined FLV and CLZ use"><entity charOffset="43-45" id="DDI-PubMed.10445377.s27.e0" text="FLV" /><entity charOffset="51-53" id="DDI-PubMed.10445377.s27.e1" text="CLZ" /><pair ddi="false" e1="DDI-PubMed.10445377.s27.e0" e2="DDI-PubMed.10445377.s27.e0" /><pair ddi="false" e1="DDI-PubMed.10445377.s27.e0" e2="DDI-PubMed.10445377.s27.e1" /></sentence><sentence text=" During FLV treatment, CNO and DCLZ AUC both decreased by 18"><entity charOffset="8-10" id="DDI-PubMed.10445377.s28.e0" text="FLV" /><entity charOffset="32-34" id="DDI-PubMed.10445377.s28.e1" text="CLZ" /><entity charOffset="23-25" id="DDI-PubMed.10445377.s28.e2" text="CNO" /><entity charOffset="31-33" id="DDI-PubMed.10445377.s28.e3" text="DCLZ" /><pair ddi="false" e1="DDI-PubMed.10445377.s28.e0" e2="DDI-PubMed.10445377.s28.e0" /><pair ddi="false" e1="DDI-PubMed.10445377.s28.e0" e2="DDI-PubMed.10445377.s28.e2" /><pair ddi="false" e1="DDI-PubMed.10445377.s28.e0" e2="DDI-PubMed.10445377.s28.e3" /><pair ddi="false" e1="DDI-PubMed.10445377.s28.e0" e2="DDI-PubMed.10445377.s28.e1" /><pair ddi="false" e1="DDI-PubMed.10445377.s28.e2" e2="DDI-PubMed.10445377.s28.e2" /><pair ddi="false" e1="DDI-PubMed.10445377.s28.e2" e2="DDI-PubMed.10445377.s28.e3" /><pair ddi="false" e1="DDI-PubMed.10445377.s28.e2" e2="DDI-PubMed.10445377.s28.e1" /><pair ddi="false" e1="DDI-PubMed.10445377.s28.e3" e2="DDI-PubMed.10445377.s28.e3" /><pair ddi="false" e1="DDI-PubMed.10445377.s28.e3" e2="DDI-PubMed.10445377.s28.e1" /></sentence><sentence text="8% (P = 0" /><sentence text="07) and 9" /><sentence text="0% (P = NS), respectively" /><sentence text=" These results indicate that in-vitro evaluations may not always accurately reflect changes in drug-drug interaction observed in-vivo" /><sentence text=" Careful patient monitoring is recommended during FLV/CLZ co-administration"><entity charOffset="50-53" id="DDI-PubMed.10445377.s33.e0" text="FLV" /><entity charOffset="54-57" id="DDI-PubMed.10445377.s33.e1" text="CLZ" /><pair ddi="false" e1="DDI-PubMed.10445377.s33.e0" e2="DDI-PubMed.10445377.s33.e0" /><pair ddi="false" e1="DDI-PubMed.10445377.s33.e0" e2="DDI-PubMed.10445377.s33.e1" /></sentence><sentence text="" /></document>